These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19864082)

  • 1. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.
    Nguyen PL; Chen MH; Beard CJ; Suh WW; Renshaw AA; Loffredo M; McMahon E; Kantoff PW; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1046-52. PubMed ID: 19864082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):10-5. PubMed ID: 19395184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
    Nguyen PL; Chen MH; Renshaw AA; Loffredo M; Kantoff PW; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):337-41. PubMed ID: 19395186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
    D'Amico AV; Manola J; Loffredo M; Renshaw AA; DellaCroce A; Kantoff PW
    JAMA; 2004 Aug; 292(7):821-7. PubMed ID: 15315996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
    JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
    N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo B; Kantoff PW
    J Clin Oncol; 2008 Jun; 26(18):2979-83. PubMed ID: 18565884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.
    D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
    Cancer; 2008 Dec; 113(12):3290-7. PubMed ID: 18980297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.